2010
DOI: 10.1586/ern.10.57
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Many antiepileptic drugs (AEDs) have therapeutic applications that extend beyond epilepsy to include neuropathic pain, migraine headaches and psychiatric disorders. The risk of some AEDs has been clearly established, but for newer drugs, small sample sizes and polytherapy exposures preclude a conclusive determination of their teratogenic potential. Most women with epilepsy will require AED therapy throughout their entire pregnancy to control seizures; the vast majority of pregnancies in women with epilepsy hav… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
80
0
2

Year Published

2011
2011
2020
2020

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 118 publications
(83 citation statements)
references
References 139 publications
(168 reference statements)
1
80
0
2
Order By: Relevance
“…These drugs also induced hyper-homocysteinemia (10) . Strongest evidence indicates that valproate exposure is associated with a 1-2% risk of NTDs, a 10-to 20-fold increase over the general population and an increased risk of neurodevelopmental deficits (11,12) . Our indexed case had no genetic predisposition but was on AEDs (valproate) for over seven years.…”
Section: Discussionmentioning
confidence: 99%
“…These drugs also induced hyper-homocysteinemia (10) . Strongest evidence indicates that valproate exposure is associated with a 1-2% risk of NTDs, a 10-to 20-fold increase over the general population and an increased risk of neurodevelopmental deficits (11,12) . Our indexed case had no genetic predisposition but was on AEDs (valproate) for over seven years.…”
Section: Discussionmentioning
confidence: 99%
“…The Major CM rates for lamotrigine exposure was 3.2% (95% CI 2.1-4.9) [54] [59][60][61][62][63][64][65] (Table 1). …”
Section: Teratogenic Effects Of Epilepsy and Aedsmentioning
confidence: 99%
“…19 Although efficacy for migraine prophylaxis with anticonvulsants exists outside of pregnancy, their use during pregnancy should be avoided due to their teratogenic profile. 8,19,31 If a patient must use anticonvulsants for migraine prophylaxis, an increased dose (4 mg) of folic acid should be taken by the mother ideally 30 days before conception. 7 Topiramate is associated with orofacial clefting in animals, and may also be associated with hypospadias and low birth weight.…”
Section: Pharmacologic Preventative Treatmentmentioning
confidence: 99%